Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Ashish C. Bhatia MD, FAAD Associate Editor

Robert T. Brodell MD, FAAD Editor-in-Chief

See All Experts

story of the week

Published in Dermatology

Journal Scan / Research · November 09, 2023

Outcomes of Tildrakizumab Induction Therapy Followed by As-Needed Dosing in Patients With Mild to Moderate Psoriasis

Clinical and Experimental Dermatology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Additional Info

Guselkumab Induction Therapy Has Long-Lasting Efficacy in Patients With Mild Psoriasis

Disclosure statements are available on the authors' profiles:

Steven Feldman MD, PhD

Clinical and Experimental Dermatology

Tildrakizumab induction therapy followed by as needed dosing in patients with mild-to-moderate psoriasis

Clin Exp Dermatol 2023 Oct 25;[EPub Ahead of Print], CA de Aragón, E Berna-Rico, A Goas, J Pérez-Bootello, MA Ballester-Martinez, P Jaén, A Blauvelt, Á González-Cantero

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Outcomes of Tildrakizumab Induction Therapy Followed by As-Needed Dosing in Patients With Mild to Moderate Psoriasis

Additional Info

Tildrakizumab induction therapy followed by as needed dosing in patients with mild-to-moderate psoriasis

Further Reading

Efficacy and Safety of Combined Topical 17α-Ethinyl Estradiol With Minoxidil vs Topical Minoxidil Alone in Patients With Female Pattern Hair Loss

Efficacy of Treatment With Secukinumab in Patients With Hidradenitis Suppurativa

Clinical Features and Treatment Outcomes Among Patients With Primary Cutaneous B-Cell Lymphomas

Clinical Characteristics and Outcomes of DPP-4 Inhibitor–Associated Bullous Pemphigoid

Efficacy and Safety of Tofacitinib vs Azathioprine in Patients With Alopecia Areata and Its Variants

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Association Between 5α-Reductase Inhibitor Use for Dermatologic Conditions and the Risk of Breast or Gynecologic Cancers

Safety and Effectiveness of a Targeted Alkali Thermolysis Patch for the Treatment of Patients With Primary Axillary Hyperhidrosis or Excessive Axillary Sweating

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

Association Between Treatment With Biologics and Cardiovascular Comorbidities in Patients With Psoriasis

Recently Updated